Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SF1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SF1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SF1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SF1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SF1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SF1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000315841 | Stomach | WIM | endothelium development | 10/426 | 136/18723 | 1.11e-03 | 1.63e-02 | 10 |
GO:00321031 | Stomach | WIM | positive regulation of response to external stimulus | 20/426 | 427/18723 | 1.96e-03 | 2.41e-02 | 20 |
GO:000188531 | Stomach | WIM | endothelial cell development | 6/426 | 64/18723 | 3.30e-03 | 3.41e-02 | 6 |
GO:006102831 | Stomach | WIM | establishment of endothelial barrier | 5/426 | 46/18723 | 3.79e-03 | 3.71e-02 | 5 |
GO:00712143 | Stomach | WIM | cellular response to abiotic stimulus | 16/426 | 331/18723 | 3.96e-03 | 3.84e-02 | 16 |
GO:01040043 | Stomach | WIM | cellular response to environmental stimulus | 16/426 | 331/18723 | 3.96e-03 | 3.84e-02 | 16 |
GO:004544631 | Stomach | WIM | endothelial cell differentiation | 8/426 | 118/18723 | 5.59e-03 | 4.78e-02 | 8 |
GO:004348430 | Thyroid | HT | regulation of RNA splicing | 46/1272 | 148/18723 | 4.82e-19 | 6.71e-16 | 46 |
GO:000838028 | Thyroid | HT | RNA splicing | 84/1272 | 434/18723 | 1.23e-18 | 1.14e-15 | 84 |
GO:000037527 | Thyroid | HT | RNA splicing, via transesterification reactions | 66/1272 | 324/18723 | 4.86e-16 | 2.08e-13 | 66 |
GO:000037727 | Thyroid | HT | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 65/1272 | 320/18723 | 9.43e-16 | 3.50e-13 | 65 |
GO:000039827 | Thyroid | HT | mRNA splicing, via spliceosome | 65/1272 | 320/18723 | 9.43e-16 | 3.50e-13 | 65 |
GO:004802429 | Thyroid | HT | regulation of mRNA splicing, via spliceosome | 34/1272 | 101/18723 | 1.32e-15 | 4.57e-13 | 34 |
GO:005068426 | Thyroid | HT | regulation of mRNA processing | 39/1272 | 137/18723 | 6.30e-15 | 1.95e-12 | 39 |
GO:190331127 | Thyroid | HT | regulation of mRNA metabolic process | 56/1272 | 288/18723 | 6.33e-13 | 1.47e-10 | 56 |
GO:200123330 | Thyroid | HT | regulation of apoptotic signaling pathway | 63/1272 | 356/18723 | 1.87e-12 | 4.01e-10 | 63 |
GO:002261330 | Thyroid | HT | ribonucleoprotein complex biogenesis | 74/1272 | 463/18723 | 4.05e-12 | 8.05e-10 | 74 |
GO:002261830 | Thyroid | HT | ribonucleoprotein complex assembly | 43/1272 | 220/18723 | 2.57e-10 | 3.25e-08 | 43 |
GO:007182630 | Thyroid | HT | ribonucleoprotein complex subunit organization | 43/1272 | 227/18723 | 7.18e-10 | 8.12e-08 | 43 |
GO:000038025 | Thyroid | HT | alternative mRNA splicing, via spliceosome | 22/1272 | 77/18723 | 4.63e-09 | 4.23e-07 | 22 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SF1 | SNV | Missense_Mutation | novel | c.1782G>A | p.Met594Ile | p.M594I | Q15637 | protein_coding | tolerated_low_confidence(0.12) | benign(0.003) | TCGA-AC-A3OD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1080N>G | p.Asp360Glu | p.D360E | Q15637 | protein_coding | tolerated(0.21) | benign(0.014) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1721N>C | p.Gln574Pro | p.Q574P | Q15637 | protein_coding | deleterious_low_confidence(0.01) | benign(0.293) | TCGA-E2-A154-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SF1 | SNV | Missense_Mutation | | c.1138N>T | p.Arg380Trp | p.R380W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-WT-AB44-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SF1 | SNV | Missense_Mutation | novel | c.877N>C | p.Glu293Gln | p.E293Q | Q15637 | protein_coding | tolerated(0.11) | probably_damaging(0.997) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1138C>T | p.Arg380Trp | p.R380W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | rs777252081 | c.1297C>T | p.Arg433Trp | p.R433W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1138C>T | p.Arg380Trp | p.R380W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1138N>T | p.Arg380Trp | p.R380W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SF1 | SNV | Missense_Mutation | novel | c.806N>C | p.Gln269Pro | p.Q269P | Q15637 | protein_coding | tolerated(0.22) | probably_damaging(0.992) | TCGA-VS-A9UT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |